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Abstract
Lymph node involvement in pancreatic adenocarcinoma (PAC) predicts postresection survival, but 
early lymph node metastasis detection is not easily accomplished. We assessed a panel of 
microRNAs (miRNAs) in a common hepatic artery lymph node (station 8) that is readily 
accessible during pancreatoduodenectomy (PD) to determine if increased miRNA levels correlate 
with postresection recurrence. Station 8 lymph nodes overlying the common hepatic artery 
collected during PD were assayed for miRNA-10b, miRNA-30c, miRNA-21, and miRNA-155 and 
cytokeratin-19 (CK19), an epithelial cell marker, using quantitative PCR. Expression was 
correlated with disease recurrence, recurrence-free survival (RFS), and overall survival (OS). 
Station 8 lymph nodes from 37 patients (30 periampullary carcinomas (PCs), 2 chronic 
pancreatitis, 5 other cancers) exhibited increased miRNA-10b levels in 14/30 PCs, and in 10 of 
these 14 patients, cancer recurred during the study period (2012–2015). High miRNA-10b was 
also associated with shorter RFS (42.5 vs. 92.4 weeks, p < 0.05) but not OS, whereas miRNA-30c, 
miRNA-21, and miRNA-155 levels and CK19 mRNA levels in station 8 nodes were variable and 
did not correlate with RFS or OS. We conclude that elevated miRNA-10b levels in station 8 lymph 
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nodes could be utilized to assess risk for early disease progression in patients with periampullary 
tumors.
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Introduction
Periampullary adenocarcinomas comprise a heterogeneous group of neoplasms at the head 
of the pancreas and denotes dismal prognosis with 5-year survival ranging from 7 to 20% 
depending on the stage and tumor type.1,2 Pancreatic adenocarcinoma (PAC), distal 
cholangiocarcinoma, and ampullary carcinoma collectively, termed periampullary cancer 
(PC), account for more than 50,000 cancer-related deaths in the USA annually.1–3 Curative 
pancreaticoduodenectomy (PD) remains the treatment of choice.1,3 Unfortunately, the 
majority of these cancers are not resectable at presentation, and other therapeutic modalities 
only lead to modest improvements in mortality.1,3 This dire situation is due, in part, to the 
absence of screening tests and early detection methods for these neoplasms.
To date, the extent of peripancreatic lymph node involvement is the best prognostic factor 
for resectable periampullary carcinoma.1,3–5 The utilization of biochemical markers to 
diagnose and assess prognosis for periampullary tumors is limited. Serum CA 19-9 levels 
had been used in the clinical settings to detect disease recurrence after resection. However, 
the preoperative diagnostic and prognostic capability of CA19-9 is restricted due to marginal 
sensitivity and specificity and falsely elevated readings in the setting of biliary 
obstruction.6,7 Other studies have attempted to identify additional tumor markers but none 
has proven to be superior to CA 19-9.
MicroRNAs (miRNAs) are short, non-coding RNAs that are expressed in many tissues 
where they participate in the regulation of numerous cellular processes by modulating 
mRNA stability and translation.8 In addition, miRNAs are released into the circulation and 
other bodily fluids.9 We previously reported that miRNA-10b is upregulated in the cancer 
cells in PAC, and high miRNA-10b levels are associated with poor neoadjuvant 
radiochemotherapy response, as well as shorter time to metastasis.10 Moreover, elevated 
plasma levels of miRNA-10b, miRNA-30c, miRNA-106b, and miRNA-155 can differentiate 
PAC from chronic pancreatitis.9 It is not known, however, whether miRNAs are also present 
in metastatic lymph nodes in PC. Therefore, in the present study, we measured the levels of 
these four miRNAs in the common hepatic artery lymph node, termed station 8 lymph 
node,11 to determine if they are present within this lymph node and whether their levels 
correlate with recurrence-free and/or overall survival in PC. We focused on studying miRNA 
expression in this particular lymph node because it is a common site for early metastasis11,12 
and is accessible for excisional biopsy during PD. The station 8 lymph node also lends itself 
for tissue sampling during preoperative endoscopic ultrasound.
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Methods
Patients
Patient information and specimens were collected at Indiana University Health University 
Hospital, Indianapolis, IN, USA, under the approval of primary investigators and the 
Institutional Review Board (IRB) at Indiana University School of Medicine. All patients 
signed informed consent. No patient identifying information were collected for this 
particular study or utilized during data analyses. Patients who underwent PD with collection 
of the common hepatic artery lymph node (station 8) were identified. Demographics 
including age and gender, date of recurrence and/or death, +/− adjuvant chemotherapy, and 
final pathology of both the lymph nodes and pancreatic specimens were recorded. Tumors 
with pathology other than periampullary adenocarcinoma were excluded from the study. 
Recurrence was determined by standard imaging studies (e.g. CT, PET) and/or by the 
presence of biopsy-proven lesions. Survival was calculated from the date of operation to the 
date of death (overall survival (OS)) or date of first recurrence (recurrence-free survival 
(RFS)). Patients lost to follow-up had their recurrence-free period calculated based on the 
last documented note in medical records.
miRNA Analysis
Station 8 lymph node samples were collected, flash-frozen in liquid nitrogen, and stored at 
−80 °C. RNA extraction was performed using the guanidine thiocyanate method as 
described.13 Total RNA was converted to cDNA using a high-capacity RNA-to-cDNA kit as 
per the manufacturer’s recommendations (Life Technologies). Assays for miRNA-10b, 
miRNA-21, miRNA-30c, and miRNA-155 were performed as described.9 Briefly, 10 ng of 
RNA was used with miRNA-specific reverse transcription primers and a miRNA reverse 
transcription kit, and quantitative PCR (qPCR) was performed for each miRNA using 
Taqman assay reagents (Life Technologies). miRNA levels were normalized to snoRNA135 
which served as the endogenous control. The same approach was used to assess CK19 levels 
but RPS6 was the endogenous control. Fold changes were calculated relative to chronic 
pancreatitis patients using the 2−ΔΔCt method.14
Statistical Analysis
miRNA-10b levels in PC were dichotomized based on a cutoff value of ≥1.5-fold above 
chronic pancreatitis controls and compared to patient recurrence status that was determined 
as described above. Given the non-parametric (non-normal) distribution of miRNA values, 
the Mann-Whitney U test was used to assess for significant differences between high (≥1.5-
fold) and low (≤1.5-fold) miRNA-10b levels. A p < 0.05 was considered statistically 
significant. Patient grouping for the miRNA-10b analysis was maintained in assessing the 
levels of miRNA-21, miRNA-30c, and miRNA-155 and CK19 mRNA levels. In order to 
compare the validity of utilizing lymph node histology versus miRNA levels to predict 
cancer recurrence, sensitivity and specificity were calculated for the above variables. We 
determined the differences in survival (RFS, OS) between the low and high miRNA groups 
over the follow-up time period using Kaplan-Meier log-rank survival analyses to factor in 
the effects of time on survival. Cox-regression analysis was used to determine if miRNA 
levels are independent predictors of RFS and OS. This method allowed us to analyze the 
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relative risks of multiple variables (i.e., age, gender, miRNA levels, staging) on specific 
outcomes (i.e., RFS, OS).
Results
Patient cohort
Station 8 lymph nodes were collected from 37 patients who underwent PD from 2012 to 
2015. Patient demographics are shown in Table 1. Review of pathology reports indicated that 
30 of these cases were PC (27 PAC; 3 cholangiocarcinomas), and 2 were chronic 
pancreatitis, whereas 5 were neither PC nor chronic pancreatitis and were therefore excluded 
from further analysis. The median age in the PC group was ~64, and there were 20 males 
and 10 females (Table 1). Moreover, 80 % of patients had stage IIB tumors, and 83 % 
received adjuvant radiochemotherapy (Table 1). Resection margin status, perineural 
invasion, lymphovascular invasion, and tumor size were analyzed, and no differences were 
found in these parameters between the comparison groups (Table 2). However, there was a 
statistically significant difference in the number of positive lymph nodes in recurrent versus 
non-recurrent cohort (28.36 versus 13.44 % respectively) (Table 2).
miRNA Analysis
From the miRNA panel, we first measured miRNA-10b levels in station 8 lymph nodes 
because it is expressed at high levels in pancreatic cancer cells and is the most sensitive and 
specific circulating miRNA to distinguish pancreatic ductal adenocarcinomas from chronic 
pancreatitis.7,9 In a subset of PC nodes (n = 14), miRNA-10b was increased by >1.5-fold (p 
< 0.05), but in the other PC nodes (n = 16), it did not differ from chronic pancreatitis (p = 
0.795) (Fig. 1a). PC patients in the miRNA-10b-high group (n = 10) developed recurrent 
disease, whereas only three patients with low miRNA-10b levels developed recurrence (p < 
0.01, Fisher’s exact test).
There were no differences in age or gender between recurrent and non-recurrent patients or 
the number of patients in each group who received adjuvant therapy (Table 2). Analysis for 
cancer cells in station 8 lymph nodes revealed that 5/14 (~38.5 %) patients in the recurrent 
group had obvious microscopic metastases compared with only 1/16 (~5.9 %) patients in the 
non-recurrent group (Fig. 1b). Based on histological analysis, sensitivity to predict 
recurrence was 66.7 %, whereas miRNA-10b levels predicted recurrence with 77 % 
sensitivity.
There was a tendency for the other three miRNAs in the panel (miRNA-21, miRNA-30c, and 
miRNA-155) to be upregulated in station 8 nodes in the recurrent group (Fig. 2a–c). 
However, these differences were not significant (p > 0.05). Moreover, the levels of CK-19 
mRNA, which is a marker denoting cells of the ductal epithelial origin and should reflect the 
presence of metastatic pancreatic cancer cells in lymph nodes, were similar in both PC 
groups (Fig. 2d).
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Recurrence-Free and Overall Survival
The median follow-up for all the patients in this study was 48.4 weeks (range, 2.4 to 146.8 
weeks). For survivors, the median follow-up was 49.4 weeks (range, 28.4 to 146.8 weeks). 
Kaplan-Meier survival analyses indicated that non-recurrent patients who had low 
miRNA-10b had a significantly longer RFS (p < 0.05) (Fig. 3a). However, there was no 
correlation between miRNA-10b levels and OS (Fig. 3b). Moreover, there were no 
differences in either RFS or OS based on a similar analysis of the other miRNAs examined 
(not shown). When a separate subanalysis was performed for PAC samples without the three 
cholangiocarcinomas, the correlation between high miRNA-10b levels and RFS just missed 
achieving statistical significance (p = 0.053).
Station 8 miRNA-10b Levels as an Independent Predictor of Disease-Free Versus Overall 
Survival
Cox regression analysis of age, gender, staging, and miRNA-10b was performed to 
determine if any of these factors are independent predictors of RFS versus of OS. High 
miRNA-10b was associated with a significantly increased hazard ratio (13.147) for RFS but 
not OS (Table 3). No other factors including age, gender, or staging showed a statistically 
significant increase or decrease in hazard ratio (Table 3).
Discussion
Lymph node metastasis is common in many cancers, but in contrast to carcinomas such as 
breast or melanoma, PAC and PC lack a single draining or sentinel lymph node that can be 
biopsied preoperatively to detect early metastasis. Instead, these cancers have multiple 
routes for lymphatic dissemination that vary depending on the tumor mass, its effects on 
lymphatic flow, and its location within the pancreatic parenchyma.15 Several studies have 
shown that the degree of pancreatic lymphadenopathy rather than one specific lymph node in 
the examined specimen correlates with poor prognosis.16,17 Therefore, the status of lymph 
node metastases in PAC and PC remains the most important predictor of mortality as also 
demonstrated in our study (Table 2).18,19 Unfortunately, preoperative visualization of these 
peripancreatic nodes by current imaging modalities is limited and cannot detect the presence 
of micrometastases within the lymph nodes. Moreover, preoperative endoscopic lymph node 
biopsy for histological examination may yield false-negative results due to sampling error.20 
Hence, PD is required for complete lymph node assessment and extensive lymph node 
resection may be associated with enhanced morbidity.21,22 The common hepatic artery 
lymph node is readily accessible during PD. Its location is also amenable to preoperative 
endoscopic biopsy. In the present study, we have isolated RNA from frozen station 8 lymph 
nodes collected at the time of PD and assayed the levels of CK19 mRNA and several 
miRNAs. In breast cancer and colorectal cancer, CK19 mRNA levels were shown to be 
useful for identifying lymph nodes that harbored metastatic cells.23,24 While the expression 
of CK19 in Station 8 lymph nodes implies the presence of pancreatic cancer cells in these 
nodes, there was no difference in CK19 mRNA levels between patients with recurrent versus 
non-recurrent disease. By contrast, among the miRNAs examined in the current study, high 
levels of miRNA-10b, but not the other miRNAs currently investigated, were significantly 
increased in patients who developed cancer recurrence. Moreover, high levels of 
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miRNA-10b correlated with RFS, but not OS, in patients with PC. In addition, Cox 
regression analysis indicated that elevated miRNA-10b levels were significantly correlated 
with shorter disease-free intervals independent of other factors including age, gender, and 
TNM staging. Given that traditional histologic examinations of lymph nodes only have a 
sensitivity of 66.7 % and specificity of 87 % in predicting recurrence, our findings raise the 
possibility that miRNA-10b could be a novel, more sensitive marker for metastatic lymph 
node involvement and disease recurrence in patients with PC. Moreover, a subanalysis of 
PAC indicated that there was a tendency for miRNA-10b to be elevated in patients who 
developed recurrent PAC. However, due to the small sample size, and potential for false-
negative detection rates from sampling errors, these elevated values barely missed achieving 
statistical significance.
There are three potential sources for the presence of PC-derived miRNA-10b in the station 8 
lymph node. First, metastatic pancreatic cancer cells likely express miRNA-10b. Indeed, 
miRNA-10b was initially reported as a metastasis promoter in breast cancer25,26 and 
subsequently implicated in enhancing metastasis in pancreatic, gastric, hepatic, renal, 
thyroid (follicular), and bladder carcinomas.10,27–31 Moreover, we previously reported that, 
first, the presence of high miRNA-10b levels in pancreatic cancer cells within PAC samples 
obtained by fine needle aspiration (FNA) during endoscopic ultrasonography (EUS) 
correlated with earlier disease recurrence following neoadjuvant radiochemotherapy10 and 
provided mechanistic evidence that miRNA-10b can promote epithelial-to-mesenchymal 
transition and pancreatic cancer cell invasion.32 Second, miRNAs are present in the 
circulation in PAC patients,9 where they are often bound to the Agonaute2 protein or to 
high-density lipoprotein particles,33,34 and these miRNAs may get trapped within the lymph 
node. Third, miRNA-10b is abundant in exosomes,35 which may similarly localize to the 
lymph nodes. Previously, it has been demonstrated that miRNA-203 and miRNA-205 may 
serve as markers for detecting lymph node metastases in patients with head and neck 
squamous cell cancer.36 Moreover, we recently reported that elevated miRNA levels in 
serum, including miRNA-10b, can help detect the presence of microscopic PAC.37 Thus, our 
ability to detect microRNA in the common hepatic lymph node provides an excellent adjunct 
to EUS/FNA in preoperative staging and prognostication for periampullary tumors but does 
not replace the need for EUS/FNA in preoperative planning. Our current findings, by 
highlighting the utility of common hepatic artery lymph nodes as sentinel nodes in studying 
periampullary cancer micrometastasis through the monitoring of miRNA-10b levels in these 
nodes, may therefore provide a biomarker of metastatic disease in such lymph nodes even in 
cases of early PAC. Additional studies are therefore urgently needed to explore this 
possibility.
Conclusions
Our findings suggest that the presence of miRNA-10b in station 8 lymph nodes may allow 
for the rapid and early detection of lymph node micrometastases in PC, especially since 
these lymph nodes can be sampled by EUS/FNA prior to surgical resection. However, our 
study is retrospective and is based on a small number of samples with limited duration of 
follow-up. It must therefore be viewed as a pilot study. Additional longer-term studies are 
required to determine whether miRNA-10b levels in station 8 lymph nodes may be used as a 
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biomarker for directing surgical and neoadjuvant/adjuvant therapy in periampullary tumors, 
as well as for early PAC detection, and to assess the potential utility of other miRNAs in this 
regard.
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Fig. 1. 
Elevated miRNA-10b levels in a subset of PC station 8 nodes. a Quantitative PCR for 
miRNA-10b in station 8 lymph nodes from chronic pancreatitis or PC patients shows that 
this miRNA is significantly increased in nodes from some PC patients (high, red bar; *p < 
0.05), whereas other nodes have levels that are similar to chronic pancreatitis (low, blue bar). 
Data are presented as interquartile range (IQR). b H&E staining of station 8 lymph nodes 
from PC patients with high miRNA-10b. Shown are representative images from a non-
recurrent patient with moderately differentiated PC (top) and recurrent patients with poorly 
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differentiated PC (middle) or without cancer cells (bottom) in the station 8 lymph node. 
Panels on the right are magnified images of boxed areas. Scale bars, 50 µm
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Fig. 2. 
The levels of three other miRNAs and CK 19 are similar in recurrent and non-recurrent 
patients. Quantitative PCR reveals that there are no significant differences in miRNA-21 (a), 
miRNA-30c (b), miRNA-155 (c), or CK19 (d) levels in station 8 lymph nodes from 
recurrent (red bars) or non-recurrent (blue bars) PC patients compared with chronic 
pancreatitis. Data are presented as IQR
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Fig. 3. 
High miRNA-10b levels are associated with decreased PFS. a Kaplan-Meier plots show that 
PC patients with high miRNA-10b (red lines) have shorter PFS (p < 0.05) than do patients 
with low miRNA-10b (blue lines). b By contrast, the OS between these groups is similar.
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Table 1
Periampullary carcinoma patient cohort
Adjuvant therapy
(yes), n (%)
Gender
  Male 20 16 (80)
  Female 10 9 (90)
Stage, n (%)
  IA 1 (3.33) 1 (3.33)
  IB 1 (3.33) 1 (3.33)
  IIA 4 (13.34) 1 (3.33)
  IIB 24 (80.0) 22 (73.3)
Total 30 (100) 25 (83.3)
Age (years)
  Range 47.9–84.5
  Median 64.4
Shown are the demographics and tumor staging for the PC patient cohort and the number of patients who received adjuvant radiochemotherapy
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Table 2
Recurrent versus non-recurrent patients
Recurrent Non-recurrent p value
Gender
  Male 10 10 0.7739
  Female 3 7 0.7110
  Total 13 17 0.4404
Stage, n (%)
  IA 1 (3.33) 0 (0) 0.3182
  IB 0 (0) 1 (3.33) 0.3182
  IIA 0 (13.34) 4 (13.34) 0.1445
  IIB 12 (50) 12 (50) 0.7843
Age (years)
  Range 47.9–84.5 50.4 – 82.6 0.8220
  Median 61.6 64.6
Adjuvant therapy (yes), n (%) 12 (92.3) 13 (76.5) 0.7899
Tumor size (cm)
  Range 1.8–5.2 1.4–5.5 0.6021
  Mean 3.1 3.35
R0 resection (yes), n (%) 12 (92.31) 16 (94.12) 1.0000
Perineural invasion (yes), n (%) 2 (15.38) 2 (11.76) 1.0000
Lymphovascular invasion (yes), n (%) 9 (69.23) 10 (58.82) 0.7080
Lymph node status
  No. of positive 6 3.18
  No. of examined 22.38 21.08
  % positive (mean) 28.36 13.44 0.0247
Comparison of recurrent with non-recurrent patients shows that there are no differences in gender, age, or tumor stage between these groups, and 
that a similar number of patients in each group received adjuvant radiochemotherapy. No differences were detected in tumor size, perineural or 
lymphovascular invasion, or R0 resection, but there is a statistically significant difference in the number of positive lymph nodes in the recurrent 
versus non-recurrent group
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Table 3
miRNA-10b predicts progression free survival
PFS (Hz ratio) p value OS (Hz ratio) p value
miRNA-10b high group 13.147 0.03a 1.095 >0.05
Age 0.988 >0.05 1.043 >0.05
Gender 1.262 >0.05 0.990 >0.05
TNM Staging 0.102 >0.05 0.9959 >0.05
Comparison of the miRNA-10b high and low groups shows that there is a statistically significant increase in the PFS hazard (Hz) ratio in PC 
patients with elevated miRNA-10b (lowercase letter), but no differences in OS, age, gender, or stage
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